By Counterforce Health Team in Filspari (sparsentan) —

Get Filspari (Sparsentan) Covered by Humana in Illinois: Complete Appeal Guide with Templates

Quick Answer: Getting Filspari Covered by Humana in Illinois

Filspari (sparsentan) requires prior authorization from Humana and often gets denied initially. The fastest path to approval: (1) Ensure your nephrologist documents IgA nephropathy confirmed by kidney biopsy, eGFR ≥30 mL/min/1.73 m², and proteinuria ≥1.0 g/day, (2) Complete REMS enrollment with quarterly liver function tests, and (3) If denied, file an expedited appeal within 65 days by calling 1-800-867-6601. Illinois residents have strong external review rights through the Department of Insurance if internal appeals fail. Start by gathering your denial letter and clinical documentation today.

Table of Contents

Understanding Your Filspari Denial

When Humana denies Filspari (sparsentan), you'll receive a Notice of Denial of Medicare Prescription Drug Coverage. Look for these key details:

  • Denial reason code (medical necessity, formulary status, or REMS requirements)
  • Appeal deadline (65 days from the notice date)
  • Required documentation listed in the denial

Common denial reasons include missing REMS enrollment, incomplete IgA nephropathy documentation, or lack of specialist involvement. Humana's PA denial rate is approximately 3.5%, among the lowest of major insurers, but denials often stem from documentation gaps rather than medical inappropriateness.

Filspari Coverage Requirements

Coverage at a Glance

Requirement What It Means Documentation Needed
Diagnosis Primary IgA nephropathy confirmed by kidney biopsy Biopsy report with IgA deposits, MEST-C score
Kidney Function eGFR ≥ 30 mL/min/1.73 m² Recent lab results (within 30 days)
Proteinuria ≥ 1.0 g/day or equivalent UPCR 24-hour urine or spot UPCR
Specialist Care Nephrology involvement Consultation notes, prescription from nephrologist
REMS Enrollment FDA safety program participation Enrollment confirmation, pregnancy testing plan
RAS Inhibitor Trial ACE inhibitor or ARB therapy Medication history, contraindication documentation

REMS Program Requirements

Filspari requires enrollment in the FDA's Risk Evaluation and Mitigation Strategy (REMS) program due to hepatotoxicity risks. Key requirements include:

  • Quarterly liver function tests (ALT/AST every 3 months, simplified from monthly monitoring)
  • Pregnancy testing for women of childbearing potential
  • Patient counseling on liver toxicity signs

Complete REMS enrollment before submitting your prior authorization to avoid automatic denial.

Fixing Common Issues Before Appeal

Before filing an appeal, address these fixable causes:

Missing Clinical Documentation

  • Kidney biopsy results: Must show IgA deposits with immunofluorescence microscopy
  • Risk stratification: Use the International IgAN Prediction Tool to document progression risk
  • Treatment history: Document ACE inhibitor/ARB trials or contraindications

REMS Enrollment Issues

  • Verify enrollment status through the Filspari REMS program
  • Ensure quarterly monitoring schedule is established
  • Document pregnancy prevention plan if applicable

Coding Problems

  • Confirm ICD-10 code N02.8 (other forms of chronic nephritis) or N03.9 (chronic nephritis, unspecified)
  • Verify NDC number matches Humana's formulary listing

First-Level Appeal Process

Step-by-Step: Filing Your Humana Appeal

  1. Gather Required Documents (Patient/Caregiver)
    • Original denial letter
    • Insurance card and member ID
    • Complete medical records from nephrologist
    • Timeline: Immediate
  2. Complete Appeal Form (Patient or Prescriber)
  3. Submit Supporting Evidence (Prescriber)
    • Medical necessity letter addressing each denial point
    • Recent lab results and imaging
    • Timeline: Same 65-day window
  4. Choose Submission Method
    • Expedited (recommended): Call 1-800-867-6601
    • Standard: Mail to P.O. Box 14165, Lexington, KY 40512-4165
    • Fax: 1-877-556-7005
  5. Track Your Appeal
    • Humana must decide within 7 days (standard) or 72 hours (expedited)
    • Check status via Humana member portal
Clinician Corner: Your medical necessity letter should address: (1) IgA nephropathy diagnosis with biopsy confirmation, (2) disease progression risk using validated tools, (3) proteinuria targets (<0.5 g/d per KDIGO 2025), (4) contraindications to alternative therapies, and (5) monitoring plan including REMS compliance.

Peer-to-Peer Review Strategy

If your initial appeal is denied, request a peer-to-peer review by calling 1-800-867-6601. This connects your prescriber directly with Humana's medical director.

Preparation Checklist for Prescribers

  • Patient's complete IgA nephropathy history
  • International IgAN Prediction Tool results
  • KDIGO 2025 guideline references
  • Filspari clinical trial data (PROTECT study)
  • Alternative therapy failures or contraindications
  • REMS enrollment confirmation

Key Talking Points

  • Disease severity: "Patient has biopsy-proven IgA nephropathy with proteinuria of [X] g/day and eGFR decline rate of [X] mL/min/1.73m²/year"
  • Progression risk: "International prediction tool shows [X]% risk of 50% eGFR decline within 5 years"
  • Treatment rationale: "Filspari targets both endothelin and angiotensin pathways, addressing IgAN's dual pathophysiology"
  • Safety monitoring: "Patient enrolled in REMS with quarterly LFT monitoring established"

Illinois External Review Rights

If Humana denies your appeal, Illinois law provides strong external review protections through the Health Carrier External Review Act.

External Review Timeline

Step Timeline Action Required
Request External Review Within 4 months of final denial Submit Illinois DOI form
Preliminary Review 5 business days Humana verifies eligibility
IRO Assignment 1 business day Independent physician reviewer assigned
Information Submission 5 business days Submit additional evidence to IRO
IRO Decision 5 business days (max 45 days total) Binding decision issued

How to File External Review

  1. Contact Illinois Department of Insurance
  2. Required Documentation
  3. Expedited Review Available
    • For urgent medical situations
    • Decision within 24-72 hours
    • Same documentation requirements
Note: Illinois has a shorter deadline than many states—you must request external review within 4 months (not the typical 4-month window), so act promptly after your final appeal denial.

Appeal Templates and Scripts

Medical Necessity Letter Template

[Date]
Humana Medicare Part D
Prior Authorization Department

RE: [Patient Name], DOB: [Date], Member ID: [Number]
Request for Coverage Determination: Filspari (sparsentan) 400mg daily

Dear Medical Director,

I am requesting coverage for Filspari (sparsentan) for my patient with biopsy-proven primary IgA nephropathy. This request addresses the specific denial reasons outlined in your [date] determination.

**Clinical Justification:**
1. **Diagnosis**: Kidney biopsy performed [date] confirmed primary IgA nephropathy with [MEST-C score details]
2. **Disease Progression**: International IgAN Prediction Tool indicates [X]% risk of 50% eGFR decline
3. **Current Status**: Proteinuria [X] g/day, eGFR [X] mL/min/1.73m²
4. **Prior Therapies**: Patient has trialed [list ACE inhibitors/ARBs] with [outcomes]
5. **REMS Compliance**: Enrolled in Filspari REMS program with quarterly LFT monitoring

**Supporting Evidence:**
- KDIGO 2025 guidelines recommend dual-pathway inhibition for progressive IgAN
- PROTECT trial demonstrated 40% reduction in proteinuria vs. irbesartan alone
- Patient meets FDA labeling criteria for Filspari therapy

I am available for peer-to-peer discussion at [phone number]. Thank you for reconsidering this medically necessary therapy.

Sincerely,
[Physician Name, MD]
[Nephrology Board Certification]

Patient Phone Script

"Hi, I'm calling about my denied prior authorization for Filspari. My member ID is [number]. I'd like to request an expedited appeal and peer-to-peer review with my nephrologist. The denial was issued on [date], and I have supporting documentation ready to submit."

Cost-Saving Options

While appealing your denial, explore these financial assistance options:

Manufacturer Support

  • Filspari Patient Support Program: Copay assistance for eligible commercial patients
  • Income-based assistance: Available for qualifying patients
  • Free drug program: For uninsured patients meeting income criteria

Foundation Grants

Research foundations that support kidney disease patients, though verify current availability:

  • National Kidney Foundation assistance programs
  • Patient Access Network (PAN) Foundation
  • HealthWell Foundation
Counterforce Health Insight: Many patients and clinicians struggle with the complex documentation requirements for specialty drug appeals. Our platform helps streamline this process by automatically generating evidence-backed appeal letters that address each payer's specific requirements, significantly improving approval rates for medications like Filspari.

When to Escalate

Contact Illinois regulators if you experience:

  • Delayed appeal decisions beyond legal timelines
  • Requests for inappropriate documentation
  • Denial of expedited review for urgent situations

Illinois Department of Insurance

  • Consumer Helpline: (877) 527-9431
  • File a complaint online
  • Office of Consumer Health Insurance (OCHI): Specialized insurance assistance

Illinois Attorney General

  • Health Care Helpline: (877) 305-5145
  • Can intervene informally with insurers
  • Assists with complex appeal cases

FAQ

Q: How long does Humana prior authorization take for Filspari? A: Standard decisions within 72 hours of receiving complete documentation. Expedited reviews within 24 hours for urgent cases.

Q: What if Filspari is non-formulary on my Humana plan? A: You can request a formulary exception with medical necessity documentation. The drug may be covered at a predetermined cost-sharing level if approved.

Q: Can I get expedited review if my kidney function is declining? A: Yes, progressive kidney disease qualifies for expedited review. Your nephrologist should document the urgency and call 1-800-867-6601.

Q: Do I need to try other medications first (step therapy)? A: Humana typically requires ACE inhibitor or ARB trial unless contraindicated. Document previous therapies and their outcomes.

Q: What happens if my external review is denied in Illinois? A: External review decisions are binding. However, you may have additional options through Medicare appeals or federal review processes.

Q: Does insurance cover the REMS monitoring costs? A: Yes, routine lab monitoring (quarterly LFTs) is typically covered as preventive care under Medicare Part B.

About Counterforce Health: We help patients, clinicians, and specialty pharmacies navigate complex prior authorization requirements by transforming insurance denials into targeted, evidence-backed appeals. Our platform identifies denial reasons and generates point-by-point rebuttals aligned with each payer's specific policies, significantly improving approval rates for specialty medications like Filspari. Learn more about our services.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance company for specific coverage decisions. Insurance policies and requirements may vary. For personalized assistance with your specific situation, contact the resources listed above or consider working with Counterforce Health for professional appeal support.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.